Literature DB >> 20150657

A role for Sp1 in transcriptional regulation of phosphatidylethanolamine N-methyltransferase in liver and 3T3-L1 adipocytes.

Laura K Cole1, Dennis E Vance.   

Abstract

Phosphatidylcholine is made in all nucleated mammalian cells via the CDP-choline pathway. Another major pathway for phosphatidylcholine biosynthesis in liver is catalyzed by phosphatidylethanolamine N-methyltransferase (PEMT). We have now identified 3T3-L1 adipocytes as a cell culture model that expresses PEMT endogenously. We have found that PEMT mRNA and protein levels increased dramatically in 3T3-L1 cells upon differentiation to adipocytes. 5'-Deletion analysis of the PEMT promoter-luciferase constructs stably expressed in 3T3-L1 adipocytes identified a regulatory region between -471 and -371 bp (relative to the transcriptional start site). Competitive and supershift assays demonstrated binding sites for transcription factors Sp1, Sp3 (-408 to -413), and YY1 (-417 to -420). During differentiation of 3T3-L1 cells to adipocytes, the amount of Sp1 protein decreased by approximately 50% just prior to activation of PEMT. Transduction of 3T3-L1 adipocytes with retrovirus containing Sp1 cDNA demonstrated that Sp1 inhibited PEMT transcriptional activity. Similarly, short hairpin RNA directed against Sp1 in 3T3-L1 adipocytes enhanced PEMT transcriptional activation. Chromatin immunoprecipitation assays confirmed that Sp1 binds to the PEMT promoter, and this interaction decreases upon differentiation to adipocytes. These experiments directly link increased PEMT expression in adipocytes to decreased transcriptional expression of Sp1. In addition, our data established that Sp1 binding was required for tamoxifen-mediated inhibition of Pemt promoter activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20150657      PMCID: PMC2852925          DOI: 10.1074/jbc.M110.109843

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

Review 1.  The Sp-family of transcription factors.

Authors:  G Suske
Journal:  Gene       Date:  1999-10-01       Impact factor: 3.688

Review 2.  Atherosclerosis. the road ahead.

Authors:  C K Glass; J L Witztum
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

3.  Temporal gene expression analysis of monolayer cultured rat hepatocytes.

Authors:  T K Baker; M A Carfagna; H Gao; E R Dow; Q Li; G H Searfoss; T P Ryan
Journal:  Chem Res Toxicol       Date:  2001-09       Impact factor: 3.739

Review 4.  Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis.

Authors:  Paola Loria; Amedeo Lonardo; Giovanni Targher
Journal:  Clin Sci (Lond)       Date:  2008-07       Impact factor: 6.124

5.  Cooperation of E2F-p130 and Sp1-pRb complexes in repression of the Chinese hamster dhfr gene.

Authors:  Y C Chang; S Illenye; N H Heintz
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

6.  Induction of hepatocyte proliferation after partial hepatectomy is accompanied by a markedly reduced expression of phosphatidylethanolamine N-methyltransferase-2.

Authors:  M Houweling; Z Cui; L Tessitore; D E Vance
Journal:  Biochim Biophys Acta       Date:  1997-05-17

7.  A role for Sp1 in the transcriptional regulation of hepatic triacylglycerol hydrolase in the mouse.

Authors:  D N Douglas; V W Dolinsky; R Lehner; D E Vance
Journal:  J Biol Chem       Date:  2001-05-03       Impact factor: 5.157

8.  Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene.

Authors:  Nitzan Levy; Dierdre Tatomer; Candice B Herber; Xiaoyue Zhao; Hui Tang; Toby Sargeant; Lonnele J Ball; Jonathan Summers; Terence P Speed; Dale C Leitman
Journal:  Mol Endocrinol       Date:  2007-10-25

Review 9.  The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century.

Authors:  Maneesh N Singh; Pierre L Martin-Hirsch; Francis L Martin
Journal:  Med Sci Monit       Date:  2008-09

10.  Lack of phosphatidylethanolamine N-methyltransferase alters plasma VLDL phospholipids and attenuates atherosclerosis in mice.

Authors:  Yang Zhao; Brian Su; René L Jacobs; Brian Kennedy; Gordon A Francis; Emma Waddington; John T Brosnan; Jean E Vance; Dennis E Vance
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-06-11       Impact factor: 8.311

View more
  5 in total

1.  N-Myc and SP regulate phosphatidylserine synthase-1 expression in brain and glial cells.

Authors:  Guergana Tasseva; Laura Cole; Jean E Vance
Journal:  J Biol Chem       Date:  2010-11-10       Impact factor: 5.157

2.  Sequential synthesis and methylation of phosphatidylethanolamine promote lipid droplet biosynthesis and stability in tissue culture and in vivo.

Authors:  Gerd Hörl; Andrea Wagner; Laura K Cole; Roland Malli; Helga Reicher; Petra Kotzbeck; Harald Köfeler; Gerald Höfler; Sasa Frank; Juliane G Bogner-Strauss; Wolfgang Sattler; Dennis E Vance; Ernst Steyrer
Journal:  J Biol Chem       Date:  2011-03-22       Impact factor: 5.157

3.  Homocysteine as a risk factor for atherosclerosis: is its conversion to s-adenosyl-L-homocysteine the key to deregulated lipid metabolism?

Authors:  Oksana Tehlivets
Journal:  J Lipids       Date:  2011-08-01

4.  Negative regulation of DsbA-L gene expression by the transcription factor Sp1.

Authors:  Qichen Fang; Wenjing Yang; Huating Li; Wenxiu Hu; Lihui Chen; Shan Jiang; Kun Dong; Qianqian Song; Chen Wang; Shuo Chen; Feng Liu; Weiping Jia
Journal:  Diabetes       Date:  2014-07-14       Impact factor: 9.461

5.  Cloning and characterization of the human USP22 gene promoter.

Authors:  Jianjun Xiong; Xiangxin Che; Xueqin Li; Huan Yu; Zhen Gong; Weidong Li
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.